Skip to content

Melanoma/Skin Cancer Health Center

Zelboraf May Double Survival for Some Melanoma Patients

New Drug Extends Life, Lessens Pain for Many Patients With Common Form of Advanced Melanoma
Font Size
A
A
A

Drug May Buy Patients More Time continued...

The study was paid for by Hoffmann-La Roche, the company that makes the drug.

In addition to giving patients more time, researchers say the drug, which costs about $9,400 a month, helps people feel better for longer.

“We get some great responses initially, at least, so we can talk to patients with a smile compared to two years ago; it was a pretty much pessimistic view of the outcomes,” says researcher Kevin B. Kim, MD, an associate professor of melanoma medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

For patients with large tumors who are suffering from pain and discomfort, “We can shrink tumors significantly, so the pain can be improved quite dramatically,” Kim says. “People feel stronger very quickly.”

Side Effects ‘Not Trivial’

Along with those benefits, the drug does come with some significant side effects.

“The side effects are certainly reasonable for a cancer drug. They’re not trivial,” Sosman says. “A number of patients needed to have their drug held for a short time or needed to have their dose lowered, but almost all patients continued on the drug. Few stopped it.”

The most problems seen in patients taking the drug were joint pain, rash, skin that easily burns in the sun, fatigue, and hair loss. More than a quarter of patients who take the drug also develop new squamous-cell skin cancers, although those are thought to be less dangerous than the melanoma.

“These patients should be followed closely by a dermatologist, which is probably a good idea anyway,” Sosman says.

Experts who were not involved in the study said the results mark an important advance in treating melanoma, but noted that there was much more work to be done to understand why people develop resistance to the drug and eventually relapse.

“This is a very exciting drug in the sense that it provides almost all patients with BRAF-mutated melanomas a remission,” says Kim A. Margolin, MD, who leads melanoma research for the Seattle Cancer Care Alliance.

“There’s no remote chance this is going to be a cure. There may be 1% or 2% of patients who remain in very durable remissions, but everyone is scratching their heads about why they haven’t developed resistance the way everyone else has,” says Margolin, who is also a professor at the University of Washington and a member of the Fred Hutchinson Cancer Research Center, both in Seattle.

Today on WebMD

Malignant melanoma
About 40-50 percent of those who live to be 65 may get it. Here’s how to spot early.
Woman checking out tan lines
There’s a dark side to that strive for beauty. See them here.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
12 Ways to Protect Your Skin from Melanoma
ARTICLE
precancerous lesions slideshow
SLIDESHOW
 
Do You Know Your Melanoma ABCs
VIDEO
15 Cancer Symptoms Men Ignore
ARTICLE
 
screening tests for men
SLIDESHOW
Vitamin D
SLIDESHOW
 
Is That Mole Skin Cancer
VIDEO
Brilliant sun rays
Quiz
 

WebMD Special Sections